Page 13 - CPG มะเร็งปากมดลูก

แนวทางการป?องกนั และรกั ษามะเร็งปากมดลูก 7

7. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465-91.
8. American College of O, Gynecologists' Committee on Adolescent Health C, Immunization ID, Public Health Preparedness

Expert Work G. Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809. Obstet Gynecol.
2020;136(2):e15-e21.
9. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for
Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal
Wkly Rep. 2019;68(32):698-702.
10. Saslow D, Andrews KS, Manassaram-Baptiste D, Smith RA, Fontham ETH, American Cancer Society Guideline
Development G. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline
adaptation. CA Cancer J Clin. 2020;70(4):274-80.
11. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination:
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.
12. Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Deebukkham P, Kulkarni AS, Pavelyev A. The
epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand. PLoS One. 2021
Feb 11;16(2):e0245894.
13. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects
following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect
Dis. 2015;15(5):565-80.
14. Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, et al. American Society of Clinical Oncology
Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol. 2016;34(15):1803-12.
15. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated
Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 16;65(49):
1405-8.
16. Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, et al. Cost and
effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health. 2012;15(1 Suppl): S29-34.
17. Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al. Evaluation of immune response to single
dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2023 Jan 4;41(1):236-45.
18. Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, et al. Evaluation of durability of a single dose
of the bivalent HPV vaccine: The CVT trial. J Natl Cancer Inst 2020; 112(10): 1038–46.
19. Baisley K, Kemp TJ, Mugo NR, Whitworth H, Onono MA, Njoroge B, et al. Comparing one dose of HPV vaccine in
girls aged 9–14 years in Tanzania (DoRIS) with one dose in young women aged 15–20 years in Kenya (KEN SHE): an
immunobridging analysis of randomised controlled trials. Lancet Glob Health 2024; 12(3):e491–9.
20. World Health Organization Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022:
conclusions and recommendations. Weekly Epidemiol Rec 2022; 97(24): 261–76.
21. Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Tantitamit T. Cost-effectiveness analysis of single-
dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting. J
Gynecol Oncol 2024; Apr 18.